2seventy bio Inc (TSVT)
4.76
-0.17
(-3.45%)
USD |
NASDAQ |
May 03, 16:00
4.76
0.00 (0.00%)
After-Hours: 20:00
2seventy bio Research and Development Expense (Quarterly): 51.22M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 51.22M |
| September 30, 2023 | 51.32M |
| June 30, 2023 | 59.98M |
| March 31, 2023 | 68.25M |
| December 31, 2022 | 60.14M |
| September 30, 2022 | 58.16M |
| June 30, 2022 | 64.56M |
| Date | Value |
|---|---|
| March 31, 2022 | 65.88M |
| December 31, 2021 | 50.22M |
| September 30, 2021 | 61.13M |
| June 30, 2021 | 63.69M |
| March 31, 2021 | 77.57M |
| December 31, 2020 | 68.88M |
| September 30, 2020 | 72.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
50.22M
Minimum
Dec 2021
77.57M
Maximum
Mar 2021
62.37M
Average
62.41M
Median
Research and Development Expense (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.695B |
| Johnson & Johnson | 3.542B |
| Macrogenics Inc | 47.35M |
| Akebia Therapeutics Inc | 9.865M |
| Tango Therapeutics Inc | 31.34M |